Greedy Insider
DFTX Insider Trades and Greediness Scores
Definium Therapeutics, Inc. (DFTX) insider trades: since Dec 26, 2025, Greedy Insider recorded 0 open-market buys and 17 sales on Form 4 from 5 insiders. The strongest recent filing scored 86 (Strong).
Who bought and who sold
Across the last 17 scoreable Form 4 transactions in DFTX, 0 were open-market purchases and 17 were sales. The table lists the most recent filings with each one's Greediness Score, so the structurally unusual trades are easy to spot first.
| Insider | Role | Type | Shares | Date | Score | ||
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer | Sell | 14051.0 | 513845.06 | 2026-09-25 | 83 | View |
| Roberts Brandi | CFO | Sell | 3377.0 | 123496.89 | 2026-09-25 | 80 | View |
| Barrow Robert | CEO | Sell | 31550.0 | 1153783.5 | 2026-09-25 | 83 | View |
| Karlin Daniel | Chief Medical Officer | Sell | 10853.0 | 396894.22 | 2026-09-25 | 83 | View |
| Wiley Matthew T. | Chief Commercial Officer | Sell | 3097.0 | 113257.29 | 2026-09-25 | 80 | View |
| Barrow Robert | CEO | Sell | 19023.0 | 721732.6 | 2026-09-03 | 71 | View |
| Barrow Robert | CEO | Sell | 29208.0 | 1315236.2 | 2026-06-25 | 86 | View |
| Wiley Matthew T. | Chief Commercial Officer | Sell | 2867.0 | 129101.01 | 2026-06-25 | 83 | View |
| Roberts Brandi | CFO | Sell | 3013.0 | 135675.39 | 2026-06-25 | 83 | View |
| Karlin Daniel | Chief Medical Officer | Sell | 10035.0 | 451876.06 | 2026-06-25 | 86 | View |
The strongest recent filing
Barrow Robert (CEO) sold 29,208 shares of Definium Therapeutics, Inc. on Jun 25, 2026, a filing that scored 86 (Strong). It scored Strong because a senior insider was trading and it was direct personal ownership. The score describes the filing, not future returns. This is not investment advice.
Cluster activity
A cluster buy is present: 5 insiders (Barrow Robert, Wiley Matthew T., Roberts Brandi, Karlin Daniel) traded DFTX the same direction within a 7-day window. Shared conviction is a stronger structural signal than a lone trade.
How this compares with Definium Therapeutics, Inc.'s own history
Open-market buys make up 0% of the 17 scoreable DFTX transactions on record between Dec 26, 2025 and Sep 25, 2026. Comparing a filing with the company's own buy/sell mix is how you tell a routine disposal from an unusual accumulation.
Methodology and sources
Scores come from six published, user-adjustable factors (insider role, cluster activity, trade size versus the insider's own history, position impact, filing urgency, and direct versus indirect ownership). The score describes the filing, not future returns. This is not investment advice.
Key facts
- Scoreable Form 4 transactions on record: 17
- Open-market buys: 0
- Sales: 17
- Distinct insiders: 5
- Strongest recent Greediness Score: 86 (Strong)
Primary sources
Related
- Strongest filing
- DFTX in the live feed
- How the Greediness Score works
- What is a cluster buy?
- Form 4 transaction codes
The score describes the filing, not future returns. This is not investment advice.